ASCO GU 2024

BRCAAway - practice changing or hypothesis generating data?

Cabo + IO: Interesting but not practice changing?!

Combination vs. monotherapy - a great new option for high-risk patients

Is "more" always better?

Dose de-escalation in different ways

Therapy Intensification Still Neglected in mHSPC

Relugolix combined with androgen signaling in real word experience

Combination NHT + PARP makes sense

What about the clinical benefit?

Higher radiation is effective in high-risk PCA

Insights and news for mCRPC

Gleason 3+3 - cancer or not?

First positive study of IO therapy in mCRPC

Long-term dose escalation - Therapy in high-risk prostate cancers

Enzalutamide therapy as option for biochemical recurrence

Olaparib + Arbiraterone better compared to either alone

Further testing before olaparib combination

Quality of life under intensive therapy

Still a difficult time for androgenic inhibitors in mCRPC

Stockholm3 validated in multiethnic cohort

Salvage radiation with anti-androgen superior to radiation alone

Combination of cabozantinib & checkpoint inhibitor

Localized PCa - news for radiotherapy and biochemical recurrence

BRCAaway - PARP combination study

Evaluating the recombination-repair mutations in patients with mCRPC

Cognitive function in ART treatment

Kombination av cabozantinib och immunterapi

Une période encore difficile pour les inhibiteurs androgéniques dans le cancer de la prostate métastatique résistant à la castration.

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi)

Orta riskli PCa da RARP sirasinda LND dan vazgecilebilir mi?

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Kognitiv påverkan av abirateron och enzalutamid?

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO GU '24

Gleason 3+3 ska vi kalla de cancer eller inte?

BRCAAway - PARP hämmare, abiraterone eller i kombination

Post-RP salvage radyoterapi hormonoterapi ile konbine edilmeli

SEPTA calismasi: Stockholm3 un multietnik hasta grubunda validasyonu

Advances in (neo)-adjuvant treatment in urothelial cancer

The emerging field of biomarkers in bladder cancer

New standard of care, but still open questions!

ADC + ICI: new data for platinum-refractory bladder cancaer patients

Another success for an ICI?

Adjuvant therapy in urothelial carcinoma : is the equation resolved?

ASCO GU24 - Highlights in Bladder cancer

HER2 and bladder cancer

MIBC: adjuvant PD1 - all set?!

Perioperative adjuvant therapy in urothelial cancer

EV as standard in 3rd line mUC

Adjuvant Nivolumab Shows Promise in Boosting Long-Term Survivorship for High-Risk Muscle-Invasive Urothelial Carcinoma

Pembrolizumab adjuvant in bladder cancer

Should we start forgetting the Galsky Criteria in advanced urothelial carcinoma?

Update M1 urothelial cancer

Update on EV-302

Biomarker update

Highlights in bladder cancer at ASCO GU24

EV + Pembro new first-line standard in localized metastatic bladder cancer

Encore un succès pour une ICI ?

Novedades sobre EV-302

¿Deberíamos empezar a olvidarnos de los Criterios de Galsky en cancer urotelial avanzado?

Tratamiento adyuvante en cancer urotelial: ¿está resuelta la ecuación?

Terapia adyuvante perioperatoria en el cáncer de vejiga

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Subcutaneous vs. intravenous application: ready for everyday clinics?

Adjuvant therapy in kidney cancer: Is immunotherapy the answer?

Trial updates at ASCO GU24: Are the follow-up data confirmatory?

No surprise with the QoL data

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark CheckMate-9ER Trial: Prolonged Efficacy and Safety Reinforce Standard of Care in Advanced Renal Cell Carcinoma

ASCO GU24 - Highlights in renal cell carcinoma

Cabozantinib Plus Atezolizumab in Adrenocortical Carcinoma Falls Short of Expectations, Emphasizing Ongoing Need for Treatment Innovations

Overall survival benefit - Pembro after surgery

Subcutaneous Nivolumab Matches IV Formulation in Clear Cell Renal Cell Carcinoma, Paving the Way for Enhanced Therapy Delivery and Safety

Long-Term Data on NIVO+IPI in aRCC

Durable effects of Ipi-Nivo

Practice changing adjuvant therapy?!

Long-term outcome

Highlights in kidney cancer at ASCO GU24

Belzutifan: Updates on QoL

Perioperative treatment in renal cell carcinoma - did we close the circle?

Long-term follow-up of first-line trials

Better QoL with Belzutifan

Tumorburden and outcome

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Tratamiento perioperatorio en cancer renal: ¿Hemos cerrado el círculo?